Nuclear Medicine and Biology
Volume 37, Issue 1 , Pages 51-55 , January 2010

Influence of chemoresistance and p53 status on fluoro-2-deoxy-d-glucose incorporation in cancer

Received 19 August 2009 ,Revised 26 August 2009 ,Accepted 27 August 2009.

References 

  1. Goldie JH. Drug resistance in cancer: a perspective. Cancer Metastasis Rev. 2001;20:63–68
  2. Loeb LA. A mutator phenotype in cancer. Cancer Res. 2001;61:3230–3239
  3. Sood AK, Buller RE. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol. 1998;92:312–319
  4. Borst P, Pinedo HM. Drug resistance. In:  Peckham M,  Pinedo HM,  Veronesi U editor. Oxford Textbook of Oncology. New York: Oxford University; 1995;p. 586–601
  5. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322–1327
  6. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. — fundamental and molecular mechanisms of mutagenesis Mutat Res. 2001;478:23–43
  7. Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, et al. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. Clin Cancer Res. 2006;12:3459–3469
  8. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J. 2005;19:1299–1301
  9. Pfeifer GP, Besaratinia A. Mutational spectra of human cancer. Hum Genet. 2009;125:493–506
  10. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun. 2005;331:868–880
  11. Aas T, Borresen AL, Geisler S, SmithSorensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811–814
  12. Stilgenbauer S, Bullinger L, Lichter P, Dohner H German CLL Study Group (GCLLSG). Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 2002;16:993–1007
  13. Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell non-Hodgkin's lymphoma. Int J Cancer. 2000;89:313–324
  14. de Graeff P, Crijns APG, de Jong S, Boezen M, Post WJ, de Vries EGE, et al Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer. 2009;101:149–159
  15. Smith TAD. The rate limiting step for tumor FDG incorporation. Nucl Med Biol. 2001;28:1–4
  16. Herrmann K, Krause BJ, Bundschuh RA, Dechow T, Schwaiger M. Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med. 2009;39:210–232
  17. Mohan HK, Miles KA. Cost-effectiveness of Tc-99m-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med. 2009;50:376–381
  18. Higashi K, Ueda Y, Ikeda R, Kodama Y, Guo J, Matsunari I, et al. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. Nucl Med Commun. 2004;25:19–27
  19. Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008;143:769–777
  20. Seo S, Hatano E, Higashi T, Nakajima A, Hara T, Tada M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427–433
  21. Lorke DE, Kruger M, Buchert R, Bohuslavizki KH, Clausen M, Schumacher U. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J Nucl Med. 2001;42:646–654
  22. Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. P-glycoprotein expression affects F-18-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol. 2009;34:1303–1312
  23. Yamada K, Brink I, Engelhardt R. Factors influencing [F-18]2-fluoro-2-deoxy-d-glucose (F-18 FDG) accumulation in melanoma cells: is FDG a substrate of multidrug resistance (MDR)?. J Dermatol. 2005;32:335–345
  24. Bentley J, Bell SE, Quinn DM, Kellett GL, Warr JR. 2-Deoxy-d-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines. Oncol Res. 1996;8:77–84
  25. Smith TAD, Sharma RI, Wang WG, Welch AE, Schweiger LF, Collie-Duguid ESR. Decreased [F-18]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro. Nucl Med Biol. 2007;34:955–960
  26. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung NS, et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res. 2005;65:3162–3170
  27. Grimpen F, Yip D, McArthur G, Waring P, Goldstein D, Loughrey M, et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol. 2005;6:724–727
  28. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659–5667
  29. Krasznai ZT, Peli-Szabo J, Nemeth E, Balkay L, Szabo G, Goda K, et al. Paclitaxel modifies the accumulation of tumor-diagnostic tracers in different ways in P-glycoprotein-positive and negative cancer cells. Eur J Pharm Sci. 2006;28:249–256
  30. Gonzalez KD, Noltner KA, Buzin CH, Gu DQ, Wen-Fong CY, Nguyen VQ, et al. Beyond Li–Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250–1256
  31. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li–Fraumeni syndrome. J Am Med Assoc. 2008;299:1315–1319
  32. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev. 2008;27:545–554
  33. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771–775
  34. Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [F-18]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166–170
  35. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [F-18]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25:1429–1434
  36. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, et al. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:43–48
  37. Zhang ZJ, Chen JH, L Meng JJDu, Zhang L, Liu Y, et al. F-18-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer. Chin Med J. 2007;120:125–131
  38. van der Veldt AAM, Hooft L, van Diest PJ, Berkhof J, MR Buist MR, et al. Microvessel density and p53 in detecting cervical cancer by FDG PET in cases of suspected recurrence. Eur J Nucl Med Mol Imaging. 2006;33:1408–1416
  39. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [F-18]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:683–691
  40. Folpe AL, Lyles RH, Sprouse JT, Conrad EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279–1287
  41. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314–3319
  42. Schroder O, Trojan J, Zeuzem S, Baum RP. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin. 1998;37:279–285
  43. Cho SM, Park YG, Lee JM, Byun JY, Lee JM, Lee KY, et al. 18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade. Eur Radiol. 2007;17:409–417
  44. Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, et al. [F-18]fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jap J Clin Oncol. 2006;36:403–409
  45. Buck A, Schirrmeister H, Kuhn T, Shen CX, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317–1323
  46. Sasaki M, Sugio K, Kuwabara Y, Koga H, Nakagawa M, Chen T. Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer. Ann Nucl Med. 2003;17:189–196
  47. Smith TAD, Sharma RI, Thompson AM, Paulin FEM. Tumor F-18-FDG incorporation is enhanced by attenuation of p53 function in breast cancer cells in vitro. J Nucl Med. 2006;47:1525–1530
  48. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrolova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650–1653

PII: S0969-8051(09)00217-0

doi: 10.1016/j.nucmedbio.2009.08.007

Nuclear Medicine and Biology
Volume 37, Issue 1 , Pages 51-55 , January 2010

Article Tools